# | Title | Journal | Year | Citations |
---|
1 | Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial | Lancet, The | 2016 | 3,077 |
2 | Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial | Lancet, The | 2017 | 1,728 |
3 | Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial | Lancet Oncology, The | 2017 | 1,388 |
4 | EAU Guidelines on Interventional Treatment for Urolithiasis | European Urology | 2016 | 1,166 |
5 | Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial | Lancet, The | 2018 | 1,142 |
6 | Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy | Journal of Nuclear Medicine | 2015 | 907 |
7 | Diagnostic Efficacy of 68 Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer | Journal of Urology | 2016 | 659 |
8 | EAU Guidelines on Diagnosis and Conservative Management of Urolithiasis | European Urology | 2016 | 581 |
9 | Current use of PSMA–PET in prostate cancer management | Nature Reviews Urology | 2016 | 469 |
10 | Simultaneous 68Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer | European Urology | 2016 | 456 |
11 | Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT | Journal of Nuclear Medicine | 2018 | 372 |
12 | The detection rate of [11C]Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer | European Journal of Nuclear Medicine and Molecular Imaging | 2008 | 355 |
13 | Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer | European Journal of Nuclear Medicine and Molecular Imaging | 2016 | 302 |
14 | ctDNA guiding adjuvant immunotherapy in urothelial carcinoma | Nature | 2021 | 293 |
15 | Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment | Nephrology Dialysis Transplantation | 2012 | 266 |
16 | Metabolic Evaluation and Recurrence Prevention for Urinary Stone Patients: EAU Guidelines | European Urology | 2015 | 246 |
17 | Detection Efficacy of 18F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy | Journal of Nuclear Medicine | 2019 | 238 |
18 | Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Is Useless for the Detection of Local Recurrence after Radical Prostatectomy | European Urology | 1999 | 232 |
19 | Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial | Lancet Oncology, The | 2021 | 225 |
20 | Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy | Journal of Nuclear Medicine | 2016 | 213 |
21 | Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer | European Urology | 2019 | 206 |
22 | Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial | European Urology | 2019 | 197 |
23 | A single‐arm, multicenter, open‐label phase 2 study of lapatinib as the second‐line treatment of patients with locally advanced or metastatic transitional cell carcinoma | Cancer | 2009 | 196 |
24 | 99mTechnetium-based Prostate-specific Membrane Antigen–radioguided Surgery in Recurrent Prostate Cancer | European Urology | 2019 | 195 |
25 | Prostate-specific Membrane Antigen–radioguided Surgery for Metastatic Lymph Nodes in Prostate Cancer | European Urology | 2015 | 192 |
26 | 68Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report | Cancer Imaging | 2016 | 171 |
27 | Preclinical Evaluation and First Patient Application of99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer | Journal of Nuclear Medicine | 2017 | 170 |
28 | An Updated Critical Analysis of the Treatment Strategy for Newly Diagnosed High-grade T1 (Previously T1G3) Bladder Cancer | European Urology | 2010 | 169 |
29 | The Impact of Lymphadenectomy and Lymph Node Metastasis on the Outcomes of Radical Cystectomy for Bladder Cancer | European Urology | 2009 | 168 |
30 | Systemic Radioligand Therapy with 177 Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer | Journal of Urology | 2016 | 166 |
31 | Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy | Journal of Nuclear Medicine | 2017 | 163 |
32 | Matched-Pair Comparison of 68Ga-PSMA-11 PET/CT and 18F-PSMA-1007 PET/CT: Frequency of Pitfalls and Detection Efficacy in Biochemical Recurrence After Radical Prostatectomy | Journal of Nuclear Medicine | 2020 | 161 |
33 | An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer | Nature Communications | 2021 | 159 |
34 | Prevalence, Incidence Estimation, Risk Factors and Characterization of Chronic Prostatitis/Chronic Pelvic Pain Syndrome in Urological Hospital Outpatients in Italy: Results of a Multicenter Case-Control Observational Study | Journal of Urology | 2007 | 149 |
35 | Radiation Dosimetry for177Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions | Journal of Nuclear Medicine | 2017 | 144 |
36 | Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial | Lancet Oncology, The | 2015 | 137 |
37 | EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort† | European Urology | 2020 | 132 |
38 | Efficacy, Predictive Factors, and Prediction Nomograms for 68 Ga-labeled Prostate-specific Membrane Antigen–ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy | European Urology | 2018 | 129 |
39 | Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA | European Urology | 2021 | 128 |
40 | Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study | Lancet Oncology, The | 2021 | 120 |
41 | Tract Sizes in Miniaturized Percutaneous Nephrolithotomy: A Systematic Review from the European Association of Urology Urolithiasis Guidelines Panel | European Urology | 2017 | 119 |
42 | Surgery for Metastatic Urothelial Carcinoma with Curative Intent: The German Experience (AUO AB 30/05) | European Urology | 2009 | 117 |
43 | Profiling of long non-coding RNAs identifies LINC00958 and LINC01296 as candidate oncogenes in bladder cancer | Scientific Reports | 2017 | 117 |
44 | Targeting the PI3K/AKT/mTOR Pathway in Bladder Cancer | Methods in Molecular Biology | 2018 | 117 |
45 | 68Ga-PSMA-HBED-CC PET for Differential Diagnosis of Suggestive Lung Lesions in Patients with Prostate Cancer | Journal of Nuclear Medicine | 2016 | 112 |
46 | 68Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study | Journal of Nuclear Medicine | 2017 | 111 |
47 | Detection of circulating tumor cells in different stages of prostate cancer | Journal of Cancer Research and Clinical Oncology | 2013 | 108 |
48 | Comparison of integrated whole-body [11C]choline PET/MR with PET/CT in patients with prostate cancer | European Journal of Nuclear Medicine and Molecular Imaging | 2013 | 107 |
49 | Preliminary results on response assessment using 68Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy | European Journal of Nuclear Medicine and Molecular Imaging | 2018 | 107 |
50 | 68Ga-PSMA-HBED-CC Uptake in Cervical, Celiac, and Sacral Ganglia as an Important Pitfall in Prostate Cancer PET Imaging | Journal of Nuclear Medicine | 2018 | 106 |